Shamseddeen, Hani
Madathanapalli, Abhishek
Are, Vijay S.
Shah, Vijay H.
Sanyal, Arun J.
Tang, Qing
Liang, Tiebing
Gelow, Kayla
Zimmers, Teresa A.
Chalasani, Naga
Desai, Archita P. http://orcid.org/0000-0001-8731-2370
Funding for this research was provided by:
American Association for the Study of Liver Diseases (2017 Career Development Award)
National Institutes of Health (3U01AA021840-07S1)
Article History
Received: 13 July 2020
Accepted: 20 September 2020
First Online: 19 October 2020
Compliance with Ethical Standards
:
: The authors declare that they have no conflict of interest.
: For full disclosure, Dr. Naga Chalasani has ongoing paid consulting activities (or had in preceding 12 months) with NuSirt, Abbvie, Afimmune (DS Biopharma), Allergan (Tobira), Madrigal, Siemens, Foresite, Galectin, Zydus, and La Jolla. These consulting activities are generally in the areas of nonalcoholic fatty liver disease and drug hepatotoxicity. Dr. Chalasani receives research grant support from Exact Sciences, Intercept, and Galectin Therapeutics where his institution receives the funding. Over the last decade, Dr. Chalasani has served as a paid consultant to more than 35 pharmaceutical companies and these outside activities have regularly been disclosed to his institutional authorities.